Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Cue Biopharma

  • Daniel Passeri, Cue Biopharma

Cue Biopharma is dedicated to developing a robust pipeline of novel immunotherapies focused on oncology, autoimmunity and chronic infections. We are building upon fundamental immunological principles to directly engage the immune system with an unprecedented level of specificity and sophistication. Our Immuno-STAT (Selective Targeting and Alteration of T cells) Biologics platform is designed to directly engage with and modulate the activity of antigen-specific T cells in the patient’s body, offering the potential for enhanced efficacy with minimal toxicity.

  • Date:Tuesday, February 12
  • Time:10:00 AM - 10:15 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23507
  • Goal for Presentation:Provide update and build awareness with investors and potential partners
  • Company Website:www.cuebio.com
  • Company HQ City:Cambridge
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Market Cap:$110,000,000
  • Ticker:CUE
  • Exchange:NASDAQ
  • CEO/Top Company Official:Daniel R. Passeri
  • Year Founded:2015
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:CUE-10
  • Development Phase of Primary Product:Pre-Clinical
  • Additional Information/Comments:Cue Biopharma is committed to bringing selective immune modulation to patients through our Immuno-STAT Biologics platform. Our talented scientists are led by an experienced management team and supported by leading scientific and clinical advisors with deep expertise in the design and clinical development of protein biologics to treat cancer, autoimmune and chronic infectious diseases. Together, we are developing novel, targeted therapies aimed at overcoming many of the challenges facing prevailing immunotherapeutics. We are headquartered in Cambridge, MA.
Speakers
Daniel Passeri
Cue Biopharma
Back